Genetic testing company 23andMe is facing a class action lawsuit alleging that the Silicon Valley start-up misled customers with advertising for its personalized DNA test kit.
The test was marketed as a tool to help users predict their risk of developing various diseases.
The lawsuit was filed in U.S. district court of California last week. It came days after the Food and Drug Administration ordered 23andMe to halt sales of its personalized test, saying the company has failed to show that the technology is supported by science.
(Read more: 23andMe chief strikes back after FDA warning)
23andMe sells its $99 test online. Customers receive a small tube in the mail, which they return to the company with a saliva sample for DNA analysis. The company claims the analysis provides insight into users' ancestry and future health risks, including 240 conditions and diseases.
The lawsuit by San Diego resident Lisa Casey alleges that the test results are "meaningless," and that 23andMe uses false and misleading advertising to promote its services to U.S. consumers. The lawsuit seeks at least $5 million under various California state laws and estimates "tens or hundreds of thousands" of U.S. customers are entitled to damages from the company.